17 Mar - 31 Mar 2022Rights issue
RhoVac is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. The primary focus of RhoVac is to develop a cancer therapy that targets metastatic cells to prevent cancer recurrence and progression after primary tumour therapy. RhoVac was founded as a private company in Denmark 2007. In the following years the first steps in terms of development of the drug candidate, RV001, were taken. In 2015 the Swedish RhoVac AB, now headquarters, was founded, and in 2016 the company was listed on “Spotlight Stock Market”.
Read more on the company's website
The offer in summary
Record date: 11 March 2022
Subscription period: 17 March 2022 - 31 March 2022
Subscription rights: One (1) existing share in the Company entitles to one (1) unit right. Sixty-one (61) unit rights entitles to one (1) unit which consists of two (2) convertibles. One (1) convertible entitles to one (1) newly issued share.
Subscription price: 80.00 SEK per unit
The offer: Maximum 624 494 convertibles which corresponds to about 25 MSEK
Trading with unit rights: 17 March 2022 - 28 March 2022
Marketplace: Spotlight Stock Market
Financial advisor: Sedermera Corporate Finance
Subscribe through Avanza here
Subscribe through Nordnet here